Brainstorm Cell Therapeutics, Inc. (BCLI)
1.25
+0.08
(+7.07%)
USD |
OTCM |
Sep 02, 16:00
Brainstorm Cell Therapeutics Research and Development Expense (TTM) : 3.297M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.297M |
| March 31, 2026 | 3.449M |
| December 31, 2025 | 3.976M |
| September 30, 2025 | 4.842M |
| June 30, 2025 | 4.977M |
| March 31, 2025 | 4.766M |
| December 31, 2024 | 4.411M |
| September 30, 2024 | 4.373M |
| June 30, 2024 | 6.652M |
| March 31, 2024 | 8.521M |
| December 31, 2023 | 10.48M |
| September 30, 2023 | 11.23M |
| June 30, 2023 | 11.67M |
| March 31, 2023 | 13.99M |
| December 31, 2022 | 13.67M |
| September 30, 2022 | 14.90M |
| June 30, 2022 | 14.81M |
| March 31, 2022 | 13.37M |
| December 31, 2021 | 15.16M |
| September 30, 2021 | 20.38M |
| June 30, 2021 | 18.63M |
| March 31, 2021 | 20.72M |
| December 31, 2020 | 22.33M |
| September 30, 2020 | 19.70M |
| June 30, 2020 | 21.84M |
| Date | Value |
|---|---|
| March 31, 2020 | 19.70M |
| December 31, 2019 | 17.20M |
| September 30, 2019 | 14.88M |
| June 30, 2019 | 12.84M |
| March 31, 2019 | 10.77M |
| December 31, 2018 | 8.293M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | 2.867M |
| June 30, 2017 | 2.489M |
| March 31, 2017 | 2.205M |
| December 31, 2016 | 2.25M |
| September 30, 2016 | 2.753M |
| June 30, 2016 | 3.466M |
| March 31, 2016 | 4.69M |
| December 31, 2015 | 4.949M |
| September 30, 2015 | 5.766M |
| June 30, 2015 | 5.835M |
| March 31, 2015 | 5.337M |
| December 31, 2014 | 4.772M |
| September 30, 2014 | 3.978M |
| June 30, 2014 | 3.21M |
| March 31, 2014 | 3.075M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| NovelStem International Corp. | -- |
| Summit Therapeutics, Inc. | 568.74M |
| Kezar Life Sciences, Inc. | 23.12M |
| Protara Therapeutics, Inc. | 52.89M |
| Clene, Inc. | 11.48M |